TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04919239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI®
Description: Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.
Study: NCT05724823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Physical Activity Seated Exercises (V-PASE)
Description: The seated exercise program includes a variety of upper and lower limb strengthening, core strengthening, agility (fast arm and leg movements), and flexibility exercises. Participants will be supervised during each session thru videoconferencing by a trained instructor.
Study: NCT04743167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Laparoscopic treatment of endometriotic lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Up to three completed cycles of IVF
Study: NCT04594447

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Kinematic Retaining knee replacement
Description: modular knee prosthesis with a Kinematic Retaining (KR) mechanism and posterior cruciate ligament (PCL) preservation

Intervention type: DEVICE
Group type: OTHER
Intervention: Physica Cruciate Retaining knee replacement
Description: modular knee prosthesis with posterior cruciate ligament (PCL) preservation
Study: NCT06001086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamb Vedotin ,pyrotinib
Description: Disitamb Vedotin combined with pyrotinib
Study: NCT06076603

Intervention type: DRUG
Intervention: nebulized polymyxin B
Description: The experimental group received intravenous combined nebulization of polymyxin B
Study: NCT04986995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: Oral administration, once daily, at least 1 hour before or after the last daily dose of L-dopa/DDCI
Study: NCT05393284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPL-0401 Dose 1
Description: Pharmaceutical Form: Capsule; Route of Administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical Form: Capsule; Route of Administration: Oral
Study: NCT05438368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR GD2/CD70 T cells
Description: Infusion of bi-4SCAR GD2/CD70 T cells at 10\^6 cells/kg body weight via IV
Study: NCT05316701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orca-T
Description: an allogeneic stem cell and T-cell immunotherapy biologic

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: unmanipulated donor allograft
Study: NCT05773989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP2C19 genotype guided P2Y12 monotherapy
Description: Patients without a LOF-allel will receive clopidogrel monotherapy (tablet of 75mg once daily) for 6 months. Patients with a LOF-allel will receive ticagrelor (tablet of 90mg twice daily) or prasugrel (tablet of 10mg once daily) for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Standard DAPT according to current guidelines with clopidogrel (tablet of 75mg once daily) for 6 months and acetylsalicylic acid (tablet 80mg one daily) for 6 months.
Study: NCT05786833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomedine
Description: Patients will receive intraoperative dexmedetomedine intravenous infusion at a dose of 0.2µg/kg/hour.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketofol
Description: Patients will receive intraoperative ketofol (1:10 ratio of ketamine-propofol mixture) intravenous infusion with %90 of Mcfarlan dose regiment. McFarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from half to 1 and 10 mg/kg/h from 1 to 2 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline 0.9%
Description: Patients will receive intravenous infusion of equivalent volume of isotonic saline 0.9%.
Study: NCT05750537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPACT-Us
Description: A suite of tobacco cessation services supported by patient navigation designed in close partnership with patients, providers, and community stakeholders.
Study: NCT05880550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound cavitation in addition to aerobic ex
Description: Ultrasonic cavitation was turned on, the program of cavitation 40 kHz was chosen, the time was adjusted at 30 minutes. The cavitational head was moved very slowly on each abdominal segment in a small circular movement for 5 minutes. After finishing the focused ultrasound of the 6 segments of the abdomen, the skin was cleaned with cotton.~in addition to that the patients will receive aerobic exercises for 40 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercises.
Description: the patients will do aerobic training for 40 minutes on a bicycle ergometer.
Study: NCT04789278

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: Notification of coronary calcium to the patient and their clinician
Study: NCT05695937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterol
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.
Study: NCT06237985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProTaper Gold file system
Description: According to the manufacturers ' instructions, root canal treatments will be conducted with the ProTaper Gold rotary file system up to F2 for mesial canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OneShape file system
Description: According to the manufacturers ' instructions, root canal treatments will be conducted with the OneShape rotary file system up to 25/.06 for mesial canals.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TruNatomy file system
Description: According to the manufacturers ' instructions, root canal treatments will be conducted with the TruNatomy rotary file system up to 26/.04 for mesial canals.
Study: NCT05799885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro-vestibular-ocular group
Description: Neuro-vestibular-ocular exercise group (30 footballers)will do the exercises given in addition to their training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release group
Description: Manual myofascial release will be applied by the physiotherapist.(30 football players)
Study: NCT05652439

Intervention type: OTHER
Intervention: Observational retrospective data collection
Description: Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes

Intervention type: OTHER
Intervention: Observational retrospective data collection
Description: Observational retrospective data collection of the incidence of adverse cardiovascular and cerebrovascular outcomes
Study: NCT05704582

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avatar Intervention
Description: 8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Addiction supportive intervention
Description: 8 weekly sessions of 60 minutes. Possibility of 4 additional sessions.
Study: NCT06373965

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online to offline counseling
Description: * Online registration and risk assessment: Users complete an onboarding process comprised of creating an account, entering demographic data, customizing settings, and completing the baseline risk assessment.~* HIVST kit order, management, and monitoring: The platform will allow users to request HIVST kits via standard mail or self-pickup at user-preferred sites (e.g., LGBT-friendly clinics). After completing the mandatory section of the questionnaire and selecting a delivery option, a random personal identification number will be assigned by the system, which will be used to track future HIVST requests, collect HIVST results, and monitor subsequent linkage to further testing and HIV care.~* eHIVST and O2O linkage to HIV clinical services: After unsealing the test kit, participants will find a reminder card to schedule their O2O pre- and post-test e-counseling appointment.
Study: NCT05610345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placental Blood Drainage
Description: Immediately after vaginal delivery following delayed cord clamping and cutting of the cord, the cord will be unclamped and blood will be drained from the placenta until cessation of flow.
Study: NCT05695937

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytosterol
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 800mg/day of free phytosterols.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: krill oil
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: krill oil
Description: 2g/day will be provided to the participants, aiming to guarantee a minimum of 400mg/day of eicosapentaenoic (EPA) and docosahexaenoic (DHA) fatty acids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo phytosterol
Description: Placebo of phytosterol, in the same quantity of the active phytosterol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo phytosterol
Description: Placebo of phytosterol, in the same quantity of the active phytosterol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo krill oil
Description: Placebo of krill oil, in the same quantity of the active krill oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo krill oil
Description: Placebo of krill oil, in the same quantity of the active krill oil
Study: NCT06432608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fermented milk, Yakult
Description: Study subjects will be provided with a product based on fermented milk, Yakult (80mL) daily for four weeks in order to know the effects of clinical manifestation of functional constipation and short-fatty acids in the Mexican population
Study: NCT05428761

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP1
Description: Participants will receive TP1 during one experimental visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TP2
Description: Participants will receive TP2 during one experimental visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo during one experimental visit.
Study: NCT05610345

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placenta Blood Not Drained
Description: Placenta Blood Not Drained
Study: NCT05257031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven extra Nitrogen
Description: SmofKabiven extra Nitrogen contains amino acids (Aminoven®), glucose, lipids (SMOFlipid®: 30% soybean oil, 30% medium-chain triglycerides, 25% olive oil, 15% fish oil), and electrolytes.
Study: NCT04656925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Reinforcement, or incentives, in exchange for evidence of not drinking alcohol.
Study: NCT06225934

Intervention type: BEHAVIORAL
Intervention: Exercise and home program to increase lateral flexion and rotation angles
Description: Suggestions will be made to the parent/caregiver of the baby diagnosed with congenital muscular torticollis (CMT) participating in the study to increase the baby's decreasing lateral flexion and rotation angles, and parents/caregivers will be advised to integrate these suggestions into their daily routine as much as possible.These suggestions; It includes holding-carrying-breastfeeding (feeding) principles, active-passive lateral flexion and active stretching of the child and activities that will increase joint range of motion for the SCM muscle, environmental arrangements, games that enable the development of active symmetrical movements and prone activities. The home program to be implemented by parents/caregivers will continue for 6 weeks. During the evaluations, the demographic characteristics of the babies (gender, gestational age, birth weight, parental information, mother's pregnancy type, pregnancy history, Apgar score, ultrasonography values, etc.) will be recorded.
Study: NCT04259645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Bupivacaine 0.375% 20 mL
Description: 20 mL 0.375% Bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Bupivacaine 0.375% diluted to 0.1875%
Description: Each block of 0.375% Bupivacaine x 20 ml mixed (diluted) with Normal Saline Solution 20 mL (total 40 mL)
Study: NCT04832425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAX-114
Description: 40 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT06258200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender and immunization activities
Description: Household visits from community mobilizers, participation in couples communication groups, and messaging from community leaders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: Participants in the comparison group will not receive any intervention
Study: NCT06125041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelizumab+Carboplatin+Etoposide+Concurrent Radiotherapy
Description: Eligible patients will receive the following treatment schemes: adebelizumab+carboplatin+etoposide, with one treatment cycle every three weeks. After 4-6 cycles, adebelizumab maintenance therapy combined with concurrent radiotherapy will be given, and conventional radiotherapy will be given to chest lesions (2Gy\*(20-30)f), brain (3Gy\*10f)/ bone (3Gy\*10f)/ adrenal gland. Immunotherapy is suspended during radiotherapy for chest lesions and lymph nodes in mediastinum, and immunotherapy is given 1-2 weeks after radiotherapy. Radiotherapy for other metastatic lesions can be carried out simultaneously with immunotherapy.
Study: NCT06293599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular stabilization exercises
Description: the patients will receive scapular stabilization exercises in the form of scapular orientation exercises,Forward/Backward Bear Crawls,Lateral Bear Crawls and assisted stretch for pectoralis minor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality exercises
Description: The exercises described were done in a consistent manner, emphasizing low intensity, and using lightweight dumbbells (range, 3 to 30 pounds). The weight of the dumbbell was individually selected by the subject for each exercise.~1. elevation of the arm in the sagittal plane (shoulder flexion~2. elevation of the arm in the scapular plane with humeral external rotation (shoulder scaption~3. elevation of the arm in the coronal plane (shoulder abduction)~4. rowing~5. horizontal shoulder abduction~6. horizontal abduction with humeral external rotation~7. push-up with hands apart~8. push-up with a plus-normal push-up adding maximum shoulder and scapular protraction with elbows fully extended~9. dumbbell bench press~10. dumbbell military press~11. shoulder shrug~12. deceleration exercise-simulating the pitching followthrough~13. shoulder extension prone~14. shoulder internal rotation~15. shoulder external rotation~16. press-up

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regular routine exercises
Description: the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular routine exercises
Description: the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular routine exercises
Description: the patients will receive routine exercises in the form of Sleeper Stretch: Posterior Capsular Stretch, Push up, Wall slides, Kettlebell High Pull,
Study: NCT06402656

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized facemask
Description: The customized face mask will be fabricated from a 3D digital image of the patient's face obtained by means of a 3D scanner. Such a scanner consists of 6 digital SLR cameras and software capable of processing a 3-D image of the patient's face exportable as an stl file.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard facemask
Description: The standard facemask is the commercially available Petit standard facemask
Study: NCT05703711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealer
Description: MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
Study: NCT06370806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss and lifestyle intervention
Description: Interdisciplinary intervention addressing weight loss and lifestyle change including nutritional behavior change, aerobic exercise, sleep hygiene, and alcohol and tobacco cessation combined with usual care (i.e., CPAP)
Study: NCT04407871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Chinese Herbal Medicine
Description: 1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture and Chinese Herbal Medicine
Description: 1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture and Chinese Herbal Medicine
Description: 1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture and Chinese Herbal Medicine
Description: 1) acupuncture and CHM, 2) acupuncture and placebo CHM, 3) control acupuncture and CHM or 4) control acupuncture and placebo CHM by an interactive online computer program in a central office. Using a 1:1:1:1 treatment ratio, there will be 682 women assigned to each treatment group.
Study: NCT01452698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.~For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks.
Study: NCT05384444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting mimicking diet
Description: The fasting mimicking diet consists of a 5 day regimen: day 1 diet of the diet supplies \~1000 kcal (10% protein, 56% fat, 34% carbohydrate), day 2-5 are identical in formulation and provide 800 kcal (9% protein, 44% fat, 47% carbohydrate). At least 4 cyclic FMDs will be performed after operation.
Study: NCT06384638

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: topical application of coconut oil
Description: topical application of coconut oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scaling and debridement
Description: scaling and debridement

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: scaling and debridement
Description: scaling and debridement
Study: NCT05943223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Description: Post-operative piperacillin/tazobactam 100 mg/kg IV q8h (to a maximum of 4.5 g IV q8h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Post-operative normal saline 50 mL once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CefTRIAXone Injection
Description: Post-operative ceftriaxone 50 mg/kg IV once daily (to a maximum of 2 g IV once daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Injection
Description: Post-operative metronidazole 10 mg/kg IV q8h (to a maximum of 500 mg IV q8h)
Study: NCT05209750

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FAPI PET/CT
Description: This study applies the radiopharmaceutical 18Fluor-FAPI-74 (shortly called FAPI) for molecular imaging of FAP expression in vivo with FAPI PET/CT, to assess the presence and distribution of activated tumour-associated fibroblasts as a marker of tumour stroma and indirectly as a marker of CRC.
Study: NCT04883437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies